product name Bemegride
Description: Bemegride is a central nervous system stimulant and antidote for barbiturate poisoning. Ethinamate is a short-acting carbamate-derivative, sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs. The depressant effects of ethinamate are, however, generally milder than those of most barbiturates.
References: Exp Physiol. 1990 Mar;75(2):199-209; Farmaco Sci. 1986 Jan;41(1):3-22.
155.19
Formula
C8H13NO2
CAS No.
64-65-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 31 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 31 mg/mL (199.8 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422083
| In Vitro |
In vitro activity: Bemegride has an antagonistic action on the GABAA receptor, suppressing both GABA- and pentobarbitone-evoked whole-cell currents to similar extents. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Long-term oral administration to the rat of barbitone, alone or together with the analeptics bemegride or pentylenetetrazol, show that the intensity of the withdrawal syndrome generally parallels the degree of associated CNS depression. |
| Animal model | |
| Formulation & Dosage | |
| References | Exp Physiol. 1990 Mar;75(2):199-209; Farmaco Sci. 1986 Jan;41(1):3-22. |
